ERBB2 and non-small cell lung carcinoma: The ORR was 26.1% and 35%, mPFS was 2.8 and 5.7 months, and OS was 9.5 and 10.6 months in patients with HER2-overexpressing and ERBB2-mutated NSCLC, respectively.